Lite Strategy, Inc. (LITS): Depreciation & Amortization
$368.0K
Year ended 2025-06-30
$0
Trailing 12 months to 2026-03-31
+4.1%
3-year compound annual growth
+27.6%
5-year compound annual growth
+19.1%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $368.0K | -3.9% | 2025-09-26, From 2024-07-01 |
| 2024-06-30 | $383.0K | -0.8% | 2025-09-26, From 2023-07-01 |
| 2023-06-30 | $386.0K | +18.4% | 2024-09-19, From 2022-07-01 |
| 2022-06-30 | $326.0K | +14.4% | 2023-09-26, From 2021-07-01 |
| 2021-06-30 | $285.0K | +161.5% | 2022-09-08, From 2020-07-01 |
| 2020-06-30 | $109.0K | +36.3% | 2022-09-08, From 2019-07-01 |
| 2019-06-30 | $80.0K | +50.9% | 2022-05-23, From 2018-07-01 |
| 2018-06-30 | $53.0K | -37.6% | 2020-09-09, From 2017-07-01 |
| 2017-06-30 | $85.0K | +46.6% | 2019-08-28, From 2016-07-01 |
| 2016-06-30 | $58.0K | -9.4% | 2018-08-30, From 2015-07-01 |
| 2015-06-30 | $64.0K | +28.0% | 2017-09-05, From 2014-07-01 |
| 2014-06-30 | $50.0K | +11.1% | 2016-09-06, From 2013-07-01 |
| 2013-06-30 | $45.0K | +246.2% | 2015-09-02, From 2012-07-01 |
| 2012-06-30 | $13.0K | n/a | 2014-09-09, From 2011-07-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | 2025-06-30 | $368.0K | -3.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $4.01B | -58.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $384.0K | -24.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $2.00B | +13.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $6.59B | -6.0% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $7.50B | +2.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $13.84M | -2.6% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $146.0K | -16.1% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $2.31M | -7.1% |
Compare LITS, BMY, TXMD, LLY side by side · Screen every company in Pharmaceutical Preparations ↗